CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649
| Title | CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649 |
|---|---|
| Description | Abstract for ASCO GI 2023 to communicate long term efficacy and safety data from Chinese subgroup of CM649 |
| Organism | Homo sapiens |
| Data Type | Other Type of Clinical information |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA011537 |
| Release Date | 2023-01-17 |
| Submitter | lin shen (linshenpku@163.com) |
| Organization | Beijing Cancer Hospital |
| Submission Date | 2022-12-01 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX002483-01 | CA209-649 ASCO GI 2023 Abstract (Chinese) | 1 | Other Type of Clinical information | 108.0 KB | 0 | Controlled |